Vertex Pharmaceuticals Heading $600? A Stock Outlook
Investors keep asking if Vertex Pharmaceuticals is headed to $600. This article breaks down the core business, pipeli...
This page offers a quick comparison of Index Fund and Target Date for retirement, with tips on matching your plans and risk tolerance.
24,517 articlesInvestors keep asking if Vertex Pharmaceuticals is headed to $600. This article breaks down the core business, pipeli...
When markets swing downward, the smartest move is often to buy quality that pays you to wait. Here are three dividend...
Goldman Sachs and JPMorgan cut targets on Kohl’s as consumer demand cools, signaling a tougher 2026. The moves come a...
Palantir surged into focus after blowout Q1 results and a fresh Buy rating from Argus with a $190 target, raising que...
Two oil-sector players, Occidental Petroleum and Energy Transfer, duke it out for the spot in a diversified portfolio...
Realty Income is set to report Q4 2025 results after the close, with investors focused on whether the company maintai...
Space investors are watching SpaceX's stock swing as it moves from early enthusiasm to a more tempered pullback. This...
J.P. Morgan updates its U.S. Analyst Focus List for July, spotlighting a dependable dividend payer. The move comes as...
PepsiCo stock faces a fresh price prediction this popular blue-chip dividend stock, with an upside case built on inte...
Wells Fargo downgrades Nike to Equal Weight, trimming the price target amid GLP-1-driven shifts in consumer wardrobes...
Micron Technology jumped on a bold target upgrade, lifting questions about sustainability as the AI memory cycle fuel...
A senior MercadoLibre executive recently disclosed an open-market purchase, prompting questions about what this means...